OPKO Health Q2 2025 Financial Results and Business Highlights

SEC Filing 8-K (0000950170-25-100891)

OPKO Health, Inc. reported its financial results and business highlights for the second quarter of 2025. The company announced a net loss of $148.4 million, or $0.19 per share, compared to a net loss of $10.3 million, or $0.01 per share, in the same period last year. Key highlights include the advancement of the Phase 1 Epstein-Barr virus vaccine trial in collaboration with Merck, progress in ModeX's immuno-oncology portfolio, and the presentation of preclinical data on OPK-88006, a novel long-acting glucagon-like peptide-1 receptor/glucagon receptor dual agonist. Additionally, OPKO's Board of Directors authorized an additional $100 million for its common stock repurchase program, bringing the total capacity to $200 million. The company also reported consolidated total revenues of $156.8 million for the quarter, down from $182.2 million in the prior year.